Last 24 hoursStory cluster

Biogen's Alzheimer's Drug BIIB080 Advances Despite Phase 2 Setback

2 sources · 0 editorials2 factsMay 13 – May 14, 2026

Source coverage

Original publisher articles in this cluster. Broadside has not yet written editorial coverage.

Biogen pushing tau drug forward despite Alzheimer’s study failure

via BioPharma Dive1 day ago

Biogen's anti-tau Alzheimer's drug misses Phase 2 goal, but claims signs of efficacy

via endpoints.news1 day ago

← Back to home